Words by Josh Hardman, reviewed by Medical Advisor Michael Haichin. *** This morning, Irish 5-MeO-DMT drug developer GH Research shared topline data from its Phase 2b study of GH001 in treatment-resistant depression (TRD). The readout has been well-received by psychedelics insiders and investors alike, with the company’s marketcap once again entering billion-dollar territory as shares in the…
